Rebapatide is a new type of antiulcer drug, belongs to the gastric mucosal protective agent, can increase the gastric mucosal blood flow, prostaglandin E2 synthesis and gastric mucus secretion, promote the expression of epidermal growth factor and its receptor, have the role of preventing the occurrence of ulcers and promoting the healing effect of ulcers, to protect the mucosa of the gastric Chemicalbook from the hazards of a variety of ulcer-causing factors, is suitable for the treatment of gastric ulcers, acute gastritis, chronic gastritis in the acute exacerbation, gastric mucosal lesions, has high clinical application value. Rebapatide tablets were firstly listed in Japan in 1990 as a drug for gastric ulcer and acute and chronic gastritis, and were approved by China CFDA in 2001, and only 2 generic companies have been approved in China, except for the original drug listed in the market.Rebapatide Rebapatide's sales and sales volume have maintained a double growth year by year in the years of 2017-2021, and the total sales in the year of 2021 exceeded 500 million yuan, and are expected to year to exceed 700 million dollars.
language
